Burixafor (hydrobromide), CAS [[1191450-19-7]]

Produktübersicht

• Artikelname: Burixafor (hydrobromide), CAS [[1191450-19-7]]
• Artikelnummer: MCE-HY-19867A
• Hersteller Artikelnummer: HY-19867A
• Alternativnummer: MCE-HY-19867A-100MG,MCE-HY-19867A-5MG,MCE-HY-19867A-10MMX1ML,MCE-HY-19867A-50MG,MCE-HY-19867A-200MG,MCE-HY-19867A-10MG,MCE-HY-19867A-500MG,MCE-HY-19867A-25MG
• Hersteller: MedchemExpress
• Kategorie: Biochemikalien
• Alternative Synonym: TG-0054 (hydrobromide)

Produktbeschreibung

Burixafor (TG-0054) hydrobromide is a potent CXCR4 antagonist with a pIC50 of 7.4. Burixafor hydrobromide inhibits the binding of CXCL12 to CXCR4, antagonizes CXCL12-induced recruitment of Galpha and beta-arrestin2, and blocks the downstream Galpha-mediated inhibitory effect on cAMP signal transduction. Burixafor hydrobromide mobilizes CD34+ hematopoietic stem/progenitor cells (HSPC) from the bone marrow to the peripheral blood. Burixafor hydrobromide can be used for research on autologous hematopoietic stem cell transplantation (ASCT)[1][2].

Produkteigenschaften

• Molekulargewicht: 769.01
• Reinheit: 98
• CAS Nummer: [1191450-19-7]
• Formel: C27H51N8O3P.5/2HBr
• Target-Kategorie: CXCR

Anwendungsbeschreibung

• Anwendungsbeschreibung: MCE Product type: Reference compound